findmyKOL

Joerg Ermann, MD

Basic profile

Brigham and Women's Hospital

ORCIDNPI
RegionBoston, MA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2014–2022

Joerg Ermann is a Rheumatology/Immunology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 101 publications with 7,107 citations (h-index 33).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
101publications

Distinct works indexed by OpenAlex, matched via ORCID.

7,107citations

Total citations across indexed works.

33h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2014–2022

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

45 Francis St
Boston, MA 021156105

Telephone

617-732-5325

Provider last certified this registry record 19 Dec 2019.

View the NPPES registry record

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    53.4%
    TNF inhibitor18.4%
    Humira(Cf) Pen68%Enbrel Sureclick16%Humira Pen16%
    Part D<11 patients
    Interleukin-17A Antagonist9.9%
    Taltz Autoinjector57%Cosentyx Sensoready (2 Pens)43%
    Part D<11 patients

    + 5 more classes in this area

  • Musculoskeletal

    22.3%
    Nonsteroidal Anti-inflammatory Drug12.4%
    Diclofenac Sodium55%Naproxen45%
    Part D<11 patients
    Xanthine oxidase inhibitor6.2%
    Allopurinol100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    9.5%
    Corticosteroid9.5%
    Prednisone100%
    Part D19 patients
Where care is delivered (Part B)91.6% facility · 8.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 20142022 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”